Kiniksa Pharmaceuticals, Ltd.KNSANASDAQ
Loading
EBITDA Over TimeExpanding
Percentile Rank100
3Y CAGR+91.4%
Studio
Year-over-Year Change

Earnings before interest, taxes, depreciation, and amortization

3Y CAGR
+91.4%/yr
Annual compound
Percentile
P100
Near historical high
vs 3Y Ago
7x
Strong expansion
Streak
1 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$85.41M+294.5%
2024$-43.92M-92.2%
2023$-22.86M-287.7%
2022$12.18M+107.9%
2021$-154.28M-1.2%
2020$-152.42M+5.1%
2019$-160.63M-48.9%
2018$-107.87M-65.0%
2017$-65.37M-172.6%
2016$-23.98M-